Cited by 102Cancer Immunotherapy and BiomarkersEpigenetics and DNA MethylationImmunotherapy and Immune Responses

The DOI matches its Crossref record; 145 of the 152 references it cites were found in a registry or an index.

Epigenetic drugs as immunomodulators for combination therapies in solid tumors

Sigalotti, Luca, Fratta, Elisabetta, Coral, Sandra, Maio, Michele·2014·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2013.12.015

Open this paper in CoChat — free account

Abstract

Continuously improving knowledge of the fine mechanisms regulating cross-talk between immune cells, and of their multi-faceted interactions with cancer cells, has prompted the development of several novel immunotherapeutic strategies for cancer treatment. Among these, modulation of the host's immune system by targeting immunological synapses has shown notable clinical efficacy in different tumor types. Despite this, objective clinical responses and, more importantly, long-term survival are achieved only by a fraction of patients; therefore, identification of the mechanism(s) responsible for the differential effectiveness of immune checkpoint blockade in specific patient populations is an area of intense investigation. Neoplastic cells can activate multiple mechanisms to escape from immune control; among these, epigenetic reprogramming is emerging as a key player. Selected tumor-associated antigens, Human Leukocyte Antigens, and accessory/co-stimulatory molecules required for efficient recognition of neoplastic cells by the immune system have been shown to be epigenetically silenced or down-regulated in cancer. Consistent with the inherent reversibility of epigenetic silencing, "epigenetic" drugs, such as inhibitors of DNA methyltransferases and of histone deacetylases, can restore the functional expression of these down-regulated molecules, thus improving the recognition of cancer cells by both the innate and adaptive immune responses. This review focuses on the immunomodulatory activity of epigenetic drugs and on their proposed clinical use in novel combined chemo-immunotherapeutic regimens for the treatment of solid tumors.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2013.12.015

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,234
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
The epigenetic progenitor origin of human cancer
Feinberg, A. P., OHLSSON, R. I., & Henikoff, S. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,885
DNA methylation in cancer: too much, but also too little
Ehrlich, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205651 · Cited by 1,563
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Suv39h-Mediated Histone H3 Lysine 9 Methylation Directs DNA Methylation to Major Satellite Repeats at Pericentric Heterochromatin
Lehnertz, B., Ueda, Y., Derijck, A. A. H. A., Braunschweig, U., Perez-Burgos, L., Kubicek, S., Chen, T., Li, E., Jenuwein, T., & Peters, A. H. F. M. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00432-9 · Cited by 1,289
Cancer epigenetics reaches mainstream oncology
Rodríguez‐Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,252
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,198

Show all 152 references

Sorted by citations

The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Immune checkpoint therapy in liver cancer
Xu, F., Jin, T., Zhu, Y., & Dai, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0777-4 · Cited by 401
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Dawson, M. A. (2017) · Science · doi:10.1126/science.aam7304 · Cited by 377
Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy
Phuengkham, H., Ren, L. F., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 306
DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Li, Q., Han, J., Yang, Y., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070961 · Cited by 255
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 205
Epigenetics and immunotherapy: The current state of play
Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 192
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Bai, J., Gao, Z., Li, X., Dong, L., Han, W., & Nie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22690 · Cited by 159
DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
Nair, V. S., Salhat, H. E., Taha, R. Z., John, A., Ali, B. R., & Elkord, E. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0512-1 · Cited by 157
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells
Gameiro, S. R., Malamas, A. S., Tsang, K. Y., Ferrone, S., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.7180 · Cited by 108
Combinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. J. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 109
Role of Methylation in Pro- and Anti-Cancer Immunity
Mehdi, A., & Rabbani, S. A. (2021) · Cancers · doi:10.3390/cancers13030545 · Cited by 102
Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy
Maio, M., Covre, A., Fratta, E., Giacomo, A. M. D., Taverna, P., Natali, P. G., Coral, S., & Sigalotti, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2914 · Cited by 100
Self-citation
Epigenetics in Cancer: A Hematological Perspective
Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 92
HDAC inhibitors as epigenetic regulators for cancer immunotherapy
Conte, M., Palma, R. D., & Altucci, L. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.03.004 · Cited by 90
A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy
Liu, Z., Ren, Y., Weng, S., Xu, H., Li, L., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.809761 · Cited by 92
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
Giacomo, A. M. D., Covre, A., Finotello, F., Rieder, D., Danielli, R., Sigalotti, L., Giannarelli, D., Petitprez, F., Lacroix, L., Valente, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1335 · Cited by 83
Self-citation
DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
Dan, H., Zhang, S., Zhou, Y., & Guan, Q. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217767 · Cited by 83
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Robert, L., Ribas, A., & Hu‐Lieskovan, S. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.001 · Cited by 72
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models
Covre, A., Coral, S., Nicolay, H. J. M., Parisi, G., Fazio, C., Colizzi, F., Fratta, E., Giacomo, A. M. D., Sigalotti, L., Natali, P. G., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1019978 · Cited by 71
Self-citation
Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy
Liu, M., Zhou, J., Chen, Z., & Cheng, A. S. L. (2016) · The Journal of Pathology · doi:10.1002/path.4832 · Cited by 69
Regulation of antitumor immunity by inflammation-induced epigenetic alterations
Karin, M., & Shalapour, S. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00756-y · Cited by 68
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
Criscuolo, D., Morra, F., Giannella, R., Visconti, R., Cerrato, A., & Celetti, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1089-z · Cited by 64
Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy
Prabhakaran, R., Thamarai, R., Sivasamy, S., Dhandayuthapani, S., Batra, J., Kamaraj, C., Karthik, K., Shah, M. A., & Mallik, S. (2024) · Epigenetics & Chromatin · doi:10.1186/s13072-024-00554-6 · Cited by 70
Cancer immunotherapy
Dhar, R., Seethy, A. A., Singh, S., Pethusamy, K., Srivastava, T. P., Talukdar, J., Rath, G. K., & Karmakar, S. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1241_20 · Cited by 59
Novel Combination Therapies for the Treatment of Bladder Cancer
Peng, M., Xiao, D., Bu, Y., Long, J., Yang, X., Lv, S., & Yang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.539527 · Cited by 54
Potential of epigenetic therapies in the management of solid tumors
Valdespino, V., & Valdespino-Castillo, P. M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s70358 · Cited by 56
Interplay Between Inflammation and Epigenetic Changes in Cancer
Maiuri, A. R., & O’Hagan, H. M. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.002 · Cited by 48
Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors
Liang, Y. J., Wang, L., Ma, P., Ju, D., Zhao, M., & Shi, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1308264 · Cited by 42
Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications
Ma, C., Cheng, J., Gu, J. H., & Wang, Q. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00373-5 · Cited by 56
Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation
Barrio‐Real, L., Benedetti, L. G., Engel, N., Tu, Y., Cho, S., Sukumar, S. V., & Kazanietz, M. G. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0441-7 · Cited by 41
New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry
Maryamchik, E., Gallagher, K., Preffer, F. I., Kadauke, S., & Maus, M. V. (2020) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21880 · Cited by 43
Decitabine: a promising epi-immunotherapeutic agent in solid tumors
Li, X., Mei, Q., Nie, J., Fu, X., & Han, W. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1002397 · Cited by 38
DNA Methylation–Targeted Drugs
Costa, E. M. D., McInnes, G., Beaudry, A., & Raynal, N. J. ‐. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000278 · Cited by 42
The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis
Oh, S. Y., Seok, J., Choi, Y. S., Lee, S. H., Bae, J.-S., & Lee, Y. M. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0026 · Cited by 36
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02628-x · Cited by 35
Self-citation
Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
Fazio, C., Covre, A., Cutaia, O., Lofiego, M. F., Tunici, P., Chiarucci, C., Cannito, S., Giacobini, G., Lowder, J. N., Ferraldeschi, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01443 · Cited by 35
Self-citation
Molecular mechanisms underlying eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma cells
Ceccarelli, V., Ronchetti, S., Marchetti, M. C., Calvitti, M., Riccardi, C., Grignani, F., & Vecchini, A. (2020) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194481 · Cited by 34
Cancer Stem Cells: Devil or Savior—Looking behind the Scenes of Immunotherapy Failure
Castagnoli, L., Santis, F. D., Volpari, T., Vernieri, C., Tagliabue, E., Nicola, M. D., & Pupa, S. M. (2020) · Cells · doi:10.3390/cells9030555 · Cited by 33
Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity
Wachowska, M., Muchowicz, A., & Gołąb, J. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00176 · Cited by 32
Epigenetics Meets Immune Checkpoints
Covre, A., Coral, S., Giacomo, A. M. D., Taverna, P., Azab, M., & Maio, M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.003 · Cited by 31
Self-citation
IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer
Buoncervello, M., Romagnoli, G., Buccarelli, M., Fragale, A., Toschi, E., Parlato, S., Lucchetti, D., Macchia, D., Spada, M., Canini, I., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8379 · Cited by 31
Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression
Natoli, M., Gallon, J., Lu, H., Amgheib, A., Pinato, D. J., Mauri, F. A., Marafioti, T., Akarca, A. U., Ullmo, I., Ip, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001519 · Cited by 33
Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?
Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2019) · Cancer · doi:10.1002/cncr.32041 · Cited by 30
Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells
Dockry, É., O’Leary, S. M., Gleeson, L. E., Lyons, J., Keane, J., Gray, S. G., & Doherty, D. G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1428156 · Cited by 29
Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors
Liu, Z., Gao, Y., & Li, X. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1552139 · Cited by 27
Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
Liu, Z.-L., Liu, J., Staiculescu, D., & Chen, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018026 · Cited by 24
The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy
Mokhtari, R. B., Sambi, M., Qorri, B., Baluch, N., Ashayeri, N., Kumar, S., Cheng, H. M., Yeger, H., Das, B., & Szewczuk, M. R. (2021) · Cancers · doi:10.3390/cancers13143596 · Cited by 25
Genome-Wide Demethylation by 5-aza-2’-Deoxycytidine Alters the Cell Fate of Stem/Progenitor Cells
Zhou, Y., & Hu, Z. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9542-z · Cited by 24
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Calabrò, L., Ceresoli, G. L., di Pietro, A., Cutaia, O., Morra, A., Ibrahim, R. A., & Maio, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1609-9 · Cited by 21
Self-citation
Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy
Lu, F., Hou, L., Wang, S., Yu, Y., Zhang, Y., Sun, L., Wang, C., Ma, Z., & Yang, F. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1927246 · Cited by 20
Epi-drugs as triple-negative breast cancer treatment
Idrissou, M., Sánchez, A., Penault-Llorca, F. M., Bignon, Y., & Bernard-Gallon, D. J. (2020) · Epigenomics · doi:10.2217/epi-2019-0312 · Cited by 22
Tumor immunotherapy—the potential of epigenetic drugs to overcome resistance
Grunewald, C. M., Schulz, W. A., Skowron, M. A., Hoffmann, M. J., & Niegisch, G. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.06.24 · Cited by 18
Genetics and Epigenetics of Glioblastoma: Therapeutic Challenges
Zayeri, Z. D., Rasras, S., Zibara, K., & Vosughi, T. (2018) · Clinical Cancer Investigation Journal · doi:10.4103/ccij.ccij_82_17 · Cited by 17
Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy
Kishi, M., Asgarova, A., Desterke, C., Chaker, D., Artus, J., Turhan, A. G., Griscelli, A. B., & Griscelli, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.729018 · Cited by 17
Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
Morante, M., Pandiella, A., Crespo, P., & Herrero, A. (2022) · Biomolecules · doi:10.3390/biom12111562 · Cited by 19
Where does PD-1 blockade fit in HL therapy?
Herrera, A. F. (2018) · Hematology · doi:10.1182/asheducation-2018.1.213 · Cited by 15
Epigenome-Driven Strategies for Personalized Cancer Immunotherapy
Rocha, G. I. Y., Gomes, J. E. M., Leite, M. L., da Cunha, N. B., & Costa, F. F. (2023) · Cancer Management and Research · doi:10.2147/cmar.s272031 · Cited by 15
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer
Cho, J. H., Öezkan, F., Koenig, M. J., Otterson, G. A., Herman, J. G., & He, K. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0110-5 · Cited by 14
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents
Oronsky, B. T., Scicinski, J. J., Kim, M. M., Cabrales, P., Salacz, M. E., Carter, C. A., Oronsky, N. C., Lybeck, H., Lybeck, M., Larson, C., et al. (2016) · Biomolecules · doi:10.3390/biom6030032 · Cited by 11
Integrated analysis from multicentre studies identities m7G-related lncRNA-derived molecular subtypes and risk stratification systems for gastric cancer
Ma, M., Li, J., Zeng, Z., Zheng, Z., & Kang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1096488 · Cited by 11
NUC041, a Prodrug of the DNA Methytransferase Inhibitor 5-aza-2′,2′-Difluorodeoxycytidine (NUC013), Leads to Tumor Regression in a Model of Non-Small Cell Lung Cancer
Daifuku, R., Grimes, S. D., & Stackhouse, M. A. (2018) · Pharmaceuticals · doi:10.3390/ph11020036 · Cited by 12
Gelated Vorinostat with inner-lysosome triggered release for tumor-targeting chemotherapy
Guo, C., Wang, Q., Zhang, X., Lu, F., Sun, M., Zeng, P., Sun, L., She, L., Wang, B., Zhang, Y., et al. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111144 · Cited by 10
Mechanism of resistance to immune checkpoint inhibitors
Pandey, M. R., & Ernstoff, M. S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.015 · Cited by 9
Unleashing precision: A review of targeted approaches in pleural mesothelioma
Occhipinti, M. A., Brambilla, M., Liello, R. D., Ambrosini, P., Lobianco, L., Leporati, R., Salvarezza, M., Vitiello, F., Marchesi, S., Manglaviti, S., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104481 · Cited by 9
Genome-Wide Microarray Expression and Genomic Alterations by Array-CGH Analysis in Neuroblastoma Stem-Like Cells
Ordóñez, R., Gallo-Oller, G., Martínez-Soto, S., Legarra, S., Pata-Merci, N., Guégan, J., Danglot, G., Bernheim, A., Meléndez, B., REY, J. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113105 · Cited by 9
Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker
Zhao, C., Liu, Y., Ju, S., & Wang, X. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s331752 · Cited by 9
Epigenetic mechanisms of liver tumor resistance to immunotherapy
Sanceau, J., & Gougèlet, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.979 · Cited by 10
Discovery and Development of HDAC Subtype Selective Inhibitor Chidamide: Potential Immunomodulatory Activity Against Cancers
Lu, X., Ning, Z., Li, Z., Pan, D., Shan, S., Guo, X., Cao, H., Yu, J., & Yang, Q. (2016) · doi:10.1002/9783527800315.ch5 · Cited by 9
Advancement in hepatocellular carcinoma research: Biomarkers, therapeutics approaches and impact of artificial intelligence
Rajak, D., Nema, P., Sahu, A., Vishwakarma, S., & Kashaw, S. K. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111120 · Cited by 9
Rewiring the solid tumor epigenome for cancer therapy
Braun, C. J., & Hemann, M. T. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1212663 · Cited by 8
Pharmacoepigenetics of Novel Nucleoside DNA Methyltransferase Inhibitors
Daifuku, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00007-3 · Cited by 8
To Identify Adenomatous Polyposis Coli Gene Mutation as a Predictive Marker of Endometrial Cancer Immunotherapy
Song, Y., Huang, J. H., Wang, K., & Li, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.935650 · Cited by 7
Adenosine Kinase on Deoxyribonucleic Acid Methylation: Adenosine Receptor-Independent Pathway in Cancer Therapy
Luo, H., Shen, H., Perkins, R. S., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.908882 · Cited by 7
Polymerized vorinostat mediated photodynamic therapy using lysosomal spatiotemporal synchronized drug release complex
Hu, P., Sun, M., Lu, F., Wang, S., Hou, L., Yu, Y., Zhang, Y., Sun, L., Yao, J., Yang, F., et al. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111903 · Cited by 6
Role of Immune Cell-Specific Hypermethylation Signatures in Classification and Risk Stratification of Breast Cancer
Chen, Y., Xia, F., Jiang, B., Wang, W., & Li, X. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.674338 · Cited by 5
Analysis of m7G-Related signatures in the tumour immune microenvironment and identification of clinical prognostic regulators in breast cancer
Huang, Q., Mo, J., Yang, H., Ji, Y., Huang, R. H., Liu, Y., & You, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-11012-z · Cited by 5
Chromatin Memory in the Development of Human Cancers
Yao, Y. (2014) · Gene Technology · doi:10.4172/2329-6682.1000114 · Cited by 4
It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective
Zaalberg, A., Pottendorfer, E., Zwart, W. T., & Bergman, A. M. (2024) · Cancers · doi:10.3390/cancers16020294 · Cited by 3
Effect of Trichostatin A on CNE2 Nasopharyngeal Carcinoma Cells - Genome-wide DNA Methylation Alteration
Yang, X., Zhang, C., Wu, H., Wu, Y., Zhang, Y.-N., Qin, M., Wu, H., Liu, X., Lina, X., & Lu, S. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.11.4663 · Cited by 3
Epigenetics and Immunotherapy: New Perspective for Breaking Chronic Viral Infection
Yan, J. (2016) · Immunotherapy Open Access · doi:10.4172/2471-9552.1000106 · Cited by 2
Combining Epigenetic and Immunotherapy in Cancer: Molecular Mechanisms
Meiliana, A., & Wijaya, A. (2023) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v15i1.2062 · Cited by 1
Efficacy of Combined Epigenetic Therapies
Raynal, N. J. ‐. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802208-5.00014-x · Cited by 1
Senescence Induced by DNA Demethylating Drugs to Treat Solid Tumors
Jueliger, S., Taverna, P., Re, O. L., & Vinciguerra, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-64597-1_166-1 · Cited by 1
Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance
Raz, D. J. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_11 · Cited by 1
Senescence Induced by DNA Demethylating Drugs to Treat Solid Tumors
Jueliger, S., Taverna, P., Re, O. L., & Vinciguerra, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_166 · Cited by 1
The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology
Giacomo, A. M. D., Covre, A., Giacobini, G., Ibrahim, R. A., Lyman, J. P., Natali, P. G., & Maio, M. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2286-x · Cited by 1
Self-citation
Molecular/Targeted Therapy of Cancer
Vail, D. M., Thamm, D. H., & Liptak, J. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-59496-7.00015-3 · Cited by 2
Cancer Epigenomics on Precision Medicine and Immunotherapy
Orozco, J. I. J., Marzese, D. M., & Hoon, D. S. �. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_68-1
THE STUDY OF ANTITUMOR ACTIVITY OF PHENYLBUTYRATE IN COMBINATION WITH 5-FLUOROURACIL ON MODEL OF EHRLICH CARCINOMA
Фадеев, Н. П., Kharisov, R. I., Eg, K., Пустовалов, Ю. И., & Fadeeva, V. L. (2017) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2017-16-1-70-75
Clinical utility of solid tumor epigenetics
Demirdizen, E., Taranda, J., & Turcan, Ş. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00013-x
Cancer Epigenomics on Precision Medicine and Immunotherapy
Orozco, J. I. J., Marzese, D. M., & Hoon, D. S. �. (2019) · Springer eBooks · doi:10.1007/978-3-319-55530-0_68
Epigenetic Drugs as Modulators of Tumor Immunogenicity and Host Immune Response
Marchi, E., Pal, I., Manavalan, J. S., Jayappa, K. D., & O’Connor, O. A. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch28
Pharmacoepigenetics of novel nucleoside DNA methyltransferase inhibitors
Daifuku, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00001-3
Additional file 1 of Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22621855
Self-citation
Additional file 4 of Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22621864
Self-citation
Additional file 3 of Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22621861
Self-citation
Additional file 5 of Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22621867
Self-citation
Additional file 2 of Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22621858
Self-citation

Authors: Sigalotti, L., Fratta, E., Coral, S., & Maio, M.
Affiliations: Centro di Riferimento Oncologico (IT)
University of Siena (IT)
Corresponding author: Maio, Michele
ORCID: Sigalotti, Luca
Fratta, Elisabetta
Coral, Sandra
Maio, Michele
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2014-06
Volume: 142
Issue: 3
Pages: 339-350
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2013.12.015
OpenAlex: W2019173523
Cited by: 102
References: 152
Citations by year: 2026: 1 · 2025: 3 · 2024: 4 · 2023: 11 · 2022: 5 · 2021: 14 · 2020: 6 · 2019: 12 · 2018: 13 · 2017: 7 · 2016: 13 · 2015: 7 · 2014: 6
FWCI: 1.25
Type: journal article
Language: en
Open access: closed
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Use Siena air (University of Siena) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: epigenetic drugs, immunomodulation, solid tumors, hypomethylating agents, histone deacetylase inhibitors, epigenetic silencing, immune checkpoint blockade, tumor immune evasion, tumor-associated antigens, costimulatory molecules, immunological synapse, cancer immunotherapy
MeSH terms: Animals, Humans, Immunologic Factors, Immunotherapy, Neoplasms, RNA Editing, Antigen Presentation, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epigenetic drugs as immunomodulators for combination therapies in solid tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks